Advertisement

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement

Aug

07

Today In Oncology

mFOLFIRINOX and S-IROX vs Nab-Paclitaxel Plus Gemcitabine in Metastatic or Recurrent Pancreatic Cancer

Alpelisib Plus Olaparib vs Single-Agent Chemotherapy in Platinum-Resistant or -Refractory HGSOC Without BRCA Mutation

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

Protease Activator Approved by the FDA for Diffuse Midline Glioma

RCC Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes

Advertisement

© 2025 HSP News Service, L.L.C.